Sarepta Therapeutics Inc (SRPT) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Total Cash From Operating Activities Chart for Sarepta Therapeutics Inc

Sarepta Therapeutics Inc (SRPT) operating cash flow for FY2025 was USD -205.5M. Sarepta Therapeutics Inc's operating cash flow moved from USD -1.8M in 1995 to USD -205.5M in 2025 over 30 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.87B
Implied Share Price
$17.73
Enterprise Value
$1.95B
Revenue (TTM)
$1.97B
EBITDA
-$17.53M
Profit Margin
-6.93%
Trailing P/E
—
Forward P/E
5.08
Price/Book (MRQ)
1.04
Price/Sales (TTM)
0.95
EV/EBITDA
16.91
EV/Revenue
0.89
Dividend Yield
—
Book Value
$14.46
Free Cash Flow (FY2025)
-$307.45M
Free Cash Flow Yield
-16.42%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.